KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Operating Expenses (2016 - 2025)

AbbVie (ABBV) has disclosed Operating Expenses for 14 consecutive years, with $12.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 27.23% to $12.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $46.1 billion, a 2.36% decrease, with the full-year FY2025 number at $46.1 billion, down 2.36% from a year prior.
  • Operating Expenses was $12.1 billion for Q4 2025 at AbbVie, down from $13.9 billion in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $16.6 billion in Q4 2024 to a low of $8.8 billion in Q1 2022.
  • A 5-year average of $10.7 billion and a median of $10.1 billion in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 77.57% in 2021, then fell 27.23% in 2025.
  • AbbVie's Operating Expenses stood at $9.8 billion in 2021, then decreased by 1.97% to $9.6 billion in 2022, then grew by 15.46% to $11.1 billion in 2023, then soared by 49.4% to $16.6 billion in 2024, then decreased by 27.23% to $12.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Operating Expenses are $12.1 billion (Q4 2025), $13.9 billion (Q3 2025), and $10.5 billion (Q2 2025).